Chai Discovery, an AI company pioneering predictive and programmable biochemical interactions to accelerate life-changing therapeutics, has announced a $70 million Series A funding round. The raise was led by Menlo Ventures, alongside their Anthology Fund in partnership with Anthropic, with participation from Yosemite, DST Global Partners, SV Angel, Avenir, DCVC, and others. Existing backers Thrive Capital, OpenAI, Dimension, Neo, Lachy Groom, and Fred Ehrsam also joined.

Founded in 2024 by Joshua Meier, Jack Dent, Matthew McPartlon, and Jacques Boitreaud, Chai Discovery aims to transform biology from science to engineering. The company recently launched Chai-2, a breakthrough in AI-driven drug discovery enabling de novo antibody design with a near-20% hit rate—dramatically outperforming traditional lab methods (0.1%) and significantly cutting time and costs.

The technology allows scientists to generate successful binders from scratch using only the target antigen and epitope, opening possibilities for faster, targeted treatments against complex diseases. Former Pfizer CSO Dr. Mikael Dolsten joins Chai’s board, bringing experience in advancing over 150 molecules into trials.

Funding will accelerate platform development, expand applications to previously inaccessible targets, and onboard strategic partners.